KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Net Income: 2017-2025

Historic Net Income for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to -$200.0 million.

  • Moderna's Net Income fell 1638.46% to -$200.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 billion, marking a year-over-year decrease of 40.11%. This contributed to the annual value of -$3.6 billion for FY2024, which is 24.46% up from last year.
  • As of Q3 2025, Moderna's Net Income stood at -$200.0 million, which was up 75.76% from -$825.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's Net Income ranged from a high of $4.9 billion in Q4 2021 and a low of -$3.6 billion during Q3 2023.
  • Its 3-year average for Net Income is -$933.7 million, with a median of -$971.0 million in 2025.
  • Its Net Income has fluctuated over the past 5 years, first soared by 2,476.07% in 2021, then plummeted by 1,638.46% in 2025.
  • Moderna's Net Income (Quarterly) stood at $4.9 billion in 2021, then plummeted by 69.91% to $1.5 billion in 2022, then tumbled by 85.19% to $217.0 million in 2023, then slumped by 616.13% to -$1.1 billion in 2024, then plummeted by 1,638.46% to -$200.0 million in 2025.
  • Its Net Income was -$200.0 million in Q3 2025, compared to -$825.0 million in Q2 2025 and -$971.0 million in Q1 2025.